E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Metastatic ER+ breast cancer. |
|
E.1.1.1 | Medical condition in easily understood language |
Metastatic ER+ breast cancer. |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
- part A: to identify the pharmacokinetic model that represents the [18F]FES kinetics most optimally and to validate simplified quantitative parameters of [18F]FES uptake. - part B: to investigate the repeatability of simplified quantitative parameters of [18F]FES uptake.
|
|
E.2.2 | Secondary objectives of the trial |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
- Histologically proven metastatic ER+ (>10% positive stained cells usingimmunohistochemistry) breast cancer on the latest biopsy - Postmenopausal females aged 18 years or older at screening. Postmenopausal status is defined as one of the following: a. age ≥60 years b. age <60 years and amenorrhea for >12 months in the absence of interfering hormonal therapies (such as LH-RH agonists and ER-antagonists) c. patient age <60 years using LH-RH agonists should continue LH-RH-agonists until after the PET procedures d. previous bilateral oophorectomy or medically confirmed ovarian failure - [18F]FDG PET, CT and/or a bone scan should be performed as part of routine clinical staging (≤4 weeks prior to screening) - Patients should have metastases in the scanning field of view, all located outside of the liver - Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0-2 - Estimated glomerular filtration rate (eGFR) ≥30 ml/min - Written and signed informed consent |
|
E.4 | Principal exclusion criteria |
- History with another cancer within the last 5 years, except cancer treated with curative intent and no evidence of disease as judged by the treating physician. - Use of selective estrogen receptor modulators (SERMs) or downregulators (SERDs) for current breast cancer such as Tamoxifen/Fulvestrant (≤5 weeks prior to screening) or investigational drug therapy - Pregnancy or lactating women - Any medical, psychological or social condition that may interfere with the subject’s safety and participation in the study, will lead to exclusion from this study
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
- part A: the most optimal pharmacokinetic model (for instance the single tissue reversible, two tissue reversible or irreversible model) will be identified. Depending on the model, the most robust and stable parameter for quantification of tracer uptake in tumor lesions (for instance the net influx rate (Ki) or volume of distribution (VT)) will be correlated with standardized uptake values (SUVs) and tumor-to-blood ratios (TBRs). - part B: repeatability of simplified measures of [18F]FES uptake, i.e. SUVs and TBRs, will be assessed.
|
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
All endpoints will be evaluated after the end of the study. |
|
E.5.2 | Secondary end point(s) |
All endpoints will be evaluated after the end of the study. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
All endpoints will be evaluated after the end of the study. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | Yes |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | No |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | |